[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mmr-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mmr-mutation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100629285","small-bowel-capsule-endoscopy-in-lynch-syndrome-100629285",false,"NCT07472686","Small Bowel Capsule Endoscopy in Lynch Syndrome","Small Bowel Capsule Endoscopy for (Pre)Neoplastic Lesion Screening in Patients With Lynch Syndrome","iCARE4Lynch","Inclusion Criteria:\n\n* Patient carrying a pathogenic variant of the DNA mismatch repair gene (MMR) (MLH1, MSH2, MSH6, PMS2, EPCAM)\n* Capsule endoscopy screening for (pre)neoplastic lesions of the small intestine\n* No opposition to the reuse of healthcare data for research purposes\n\nExclusion Criteria:\n\n* Absence of documented MMR gene variant\n* Opposition to the study","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","The impact of small bowel (SB) capsule endoscopy (CE) on the screening (followed by diagnosis and treatment) of (pre)neoplastic lesions of the small bowel in Lynch syndrome (LS) patients is unknown.\n\nThe iCARE4Lynch study is a retrospective cohort of patients carrying a pathogenic variant of the DNA mismatch repair gene (MMR) (MLH1, MSH2, MSH6, PMS2, EPCAM) who had had at least one SBCE for screening of small bowel (pre)neoplastic lesions between January 1st 2000 and December 31 2024.",[25,26,27,28,29],"MMR Mutation","Small Bowel Adenoma","Small-bowel Adenocarcinoma","Lynch Syndrome","Cancer",[29,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Lynch syndrome","Capsule endoscopy","Screening","Small bowel","Small-bowel adenoma","Small-bowel adenocarcinoma","Small-bowel cancer","Small-bowel capsule endoscopy","pathogenic variant","DNA mismatch repair gene (MMR)","MLH1","MSH2","MSH6","PMS2","EPCAM","RECRUITING","2026-03-11",{"date":49,"type":50},"2026-03-16","ACTUAL",{"date":52,"type":50},"2025-06-16",{"date":54,"type":21},"2026-12",{"name":56,"class":57},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":71,"studyType":22,"phases":4,"briefSummary":72,"conditions":73,"keywords":80,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":58},"100449217","prostate-cancer-genetic-risk-evaluation-and-screening-study-100449217","NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study","Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)","PROGRESS","Inclusion Criteria:\n\n* Men 35-74 years old\n* No known diagnosis of prostate cancer\n* Life expectancy \\>10 years\n* Meet cohort A, B, or C criteria\n* Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53)\n* Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing\n* Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black\u002FAfrican ancestry\n\nExclusion Criteria:\n\n* Prior diagnosis or treatment of prostate cancer\n* Inability to undergo prostate MRI\n* Inability to receive MRI contrast agent","MALE","35 Years","74 Years",{"count":20,"type":21},"10 Years","This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black\u002FAfrican ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.",[74,75,76,77,78,25,28,79],"Prostatic Neoplasm","Prostate Cancer","BRCA2 Mutation","BRCA1 Mutation","ATM Gene Mutation","Genetic Predisposition to Disease",[81,82,83,28,84,85],"BRCA2","BRCA1","Mismatch Repair Deficiency","HOXB13","Family History of Prostate Cancer","2024-10-05",{"date":88,"type":50},"2024-10-09",{"date":90,"type":50},"2020-02-12",{"date":92,"type":21},"2040-12",{"name":94,"class":57},"Massachusetts General Hospital"]